Levopar Plus

Quick links to important sections

Levopar Plus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levopar Plus

Property Description
Active ingredients Levodopa, Benserazide
Form Oral tablet (standard, dispersible, modified-release)
Pharmacological class Anti-Parkinson Agent (Dopaminergic Antiparkinsonism)
General use Supporting improved motor function in conditions characterized by dopamine deficiency
Origin Synthetic, Fixed-Dose Combination, Prescription-Only

Levopar Plus: Definition, Type, and Class

Levopar Plus is a synthetic, fixed-dose combination medicine classified as an Anti-Parkinson Agent and belonging to the Dopaminergic Antiparkinsonism class. This medication is formally known by its generic combination name Co-beneldopa. The combination structure, comprising two active components, is clinically recognized for its essential role in addressing specific chemical imbalances affecting motor control.

As a prescription-only product, it is supplied for oral administration primarily in the form of a tablet, which may include variations designed for quicker absorption or dispersion in liquid. This fixed-dose structure is a critical feature that defines its therapeutic strategy, differentiating it from single-agent formulations.

Composition: Active Ingredients and Their Purpose

The formula contains two distinct active ingredients: the prodrug Levodopa (L-DOPA), which is the precursor the body converts to dopamine, and Benserazide, which acts as a peripheral aromatic L-amino acid decarboxylase (AAAD) inhibitor.

This pairing is necessary because Levodopa is highly susceptible to rapid breakdown by enzymes outside the brain. Benserazide prevents this premature conversion, as the inhibitor is designed to not cross the blood-brain barrier. The general function of this design is to increase the effective delivery and bioavailability of Levodopa to the central nervous system, a key feature that supports its recognition as a gold standard in therapeutic protocols.

What is the General Function of Levopar Plus?

The general function of Levopar Plus is to support the brain’s ability to restore insufficient levels of dopamine, the chemical necessary for coordinated body movements. By effectively elevating central dopamine levels, the medicine strategically helps to mitigate physical symptoms such as rigidity or slowness of movement, thereby supporting the general purpose of maintaining or improving motor function.

What side effects are possible with Levopar Plus?

Possible side effects and safety information

The official safety profile for the Levodopa/Benserazide combination (Co-beneldopa) is documented based on classifications established by government regulatory authorities.

Adverse reactions are grouped by frequency and the body system affected, consistent with regulatory standards. Effects documented as Common include involuntary movements (dyskinesia, hyperkinesia), motor fluctuations, psychiatric disturbances (hallucinations, confusion, insomnia), and gastrointestinal issues such as nausea and vomiting. Rare effects include blood disorders such as hemolytic anemia, leukopenia, and thrombocytopenia.

Safety concerns are primarily focused on the Nervous System, Psychiatric, Gastrointestinal, and Cardiovascular Systems. Orthostatic hypotension (dizziness upon standing) and cardiac arrhythmia are documented vascular and cardiac safety observations.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents note clinically significant risks, including reports of Sudden Onset of Sleep Attacks and the potential for a Neuroleptic Malignant Syndrome (NMS)-like condition when the medication is abruptly stopped or rapidly dose-reduced. The development of certain impulse control disorders, such as pathological gambling or hypersexuality, is also a documented safety finding.

Specific time-related patterns are officially noted: gastrointestinal effects may appear mainly during the initial phase of treatment, while dyskinesias and motor fluctuations are typically associated with prolonged, long-term use.

Safety constraints and contraindications are defined for specific populations and conditions. The medication is generally not recommended for pediatric patients (under 25 years) or during pregnancy and breastfeeding. It is contraindicated in narrow-angle glaucoma, a history of melanoma, and severe decompensated hepatic or renal function.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Levopar Plus (Levodopa/Benserazide) may result in acute and severe physiological manifestations documented in regulatory materials, primarily affecting the central nervous system and the cardiovascular system. Overdose presentations include psychiatric disturbances, profound mental confusion, and severe, uncontrolled involuntary movements known as dyskinesia. Cardiovascular effects can involve significant irregularities in heart rhythm, such as a fast, slow, or irregular heartbeat, alongside severe blood pressure fluctuations, including initial hypertension followed by prolonged symptomatic hypotension. Gastrointestinal effects like severe nausea and vomiting are also noted.

Mandatory Emergency Actions

Immediate medical attention is required for any suspected or confirmed overdose, even if the individual remains without symptoms after taking more than the prescribed dose. You must go to a hospital straight away and bring the medicine pack. Urgent medical services should be contacted immediately if severe signs develop, such as an irregular heartbeat or signs of internal bleeding, including blood in vomit or black feces. The management of overdose is strictly supportive and symptomatic, as no specific antidote is known for this combination. Continuous monitoring of cardiac rhythm and vital signs is required in a hospital setting for clinical observation.

Therapeutic Uses of Levopar Plus

What Levopar Plus treats: main uses and benefits

Levopar Plus, which combines carbidopa and levodopa, is used across domains where additional symptomatic support is needed. The main therapeutic application is considered relevant for managing Parkinson's disease (PD), a condition characterized by periods of heightened symptoms that are linked to organ-specific functional stress.

This combination therapy may assist with managing symptoms of increased neurological or muscular activity. The medication is indicated for the treatment of PD, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide or manganese intoxication. This listing covers conditions associated with acute or disruptive episodes.

The medication helps address symptom clusters that interfere with daily functioning, such as tremor (involuntary shaking), rigidity (stiffness), and bradykinesia (slowness of movement). When symptoms intensify, supportive relief is needed. As a clinical benefit, this medication contributes to improved comfort during periods of heightened symptoms.

“This supports patients during difficult episodes by easing distress and may assist with maintaining functional stability.”

Quick Fact: Support for Stiffness (Rigidity)

The use of this medication plays a role in managing the overall symptom load for patients experiencing episodic or fluctuating manifestations of their condition.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

This section outlines the eligibility and non-eligibility for Levopar Plus (Co-beneldopa) based strictly on authoritative governmental regulatory documents.

Classification Eligibility Rule Condition/Restriction
Allowed Population Adults (generally over 25) with Parkinson’s disease and specific parkinsonism types. Careful titration and monitoring required for older adults.
Absolute Contraindication Patients with known hypersensitivity to levodopa, benserazide, or excipients. Excludes immediate use.
Age Restriction Under 25 years old Contraindicated, as skeletal development must be complete.
Pregnancy/Lactation Pregnant women or women of childbearing potential without adequate contraception. Contraindicated. Also not recommended during breastfeeding.
Comorbidity Exclusion Decompensated endocrine, renal, or hepatic function; severe cardiac disorders; psychiatric diseases with a psychotic component; closed-angle glaucoma. Absolute prohibition on use.
Drug Interaction Concurrent use of non-selective Monoamine Oxidase (MAO) inhibitors. Absolute prohibition due to risk of hypertensive crisis.
Restricted Use Mild-to-moderate renal insufficiency (creatinine clearance ge 30 mL/min). No dose reduction is typically considered necessary.

Official regulatory documents define the eligibility profile by establishing a rigorous set of absolute contraindications—covering age, reproductive status, certain life-threatening comorbid conditions, and specific drug interactions—that strictly prohibit the use of Levopar Plus. The label also explicitly restricts use for specific non-indications, such as drug-induced parkinsonism, and details conditional use requirements for populations like those with open-angle glaucoma or a history of arrhythmia, where use is permitted only with special monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Levopar Plus (Levodopa/Benserazide) is defined by official regulatory documentation outlining specific drug-drug, drug-food, and substance restrictions.

Contraindicated Combinations

Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited due to the significant risk of a hypertensive crisis. A mandatory wash-out period of at least two weeks is required after discontinuing these MAOIs before initiating Levopar Plus therapy.

Pharmacodynamic and Absorption Interactions

Several medicinal products exhibit documented pharmacodynamic interactions. Antipsychotic agents (neuroleptics) and certain opioids may counteract the effectiveness of the medication by opposing its central action. Conversely, co-administration with antihypertensive agents may lead to additive hypotensive effects. When taken with General Anaesthetics such as Halothane, there is an increased risk of cardiac arrhythmias, requiring discontinuation before surgery.

Absorption interactions are also documented. Iron salts (Ferrous sulfate) and high-protein meals can reduce the bioavailability and absorption of Levodopa due to competitive effects, necessitating dose separation.

Mechanism of Action

The mechanism of action for Levopar Plus is a two-part strategy—peripheral protection and central conversion—targeting a specific neurotransmitter deficit in the brain's motor control circuits.

Selective Enzyme Protection and Central Delivery

The mechanism functions as a coordinated transport system. It utilizes Benserazide to selectively inhibit the enzyme Aromatic L-amino acid decarboxylase (AADC) in the body's periphery. This prevents the premature breakdown of the inactive precursor, Levodopa, increasing the concentration that passes the specialized blood-brain barrier and reaches the Central Nervous System.

Dopamine Synthesis and Motor Pathway Modulation

Once inside the CNS, Levodopa is rapidly converted into the active neurotransmitter, Dopamine, by the AADC enzyme in surviving neurons. This new dopamine then acts as an agonist, activating the postsynaptic Dopamine Receptors (D1 to D5) in the striatum. This targeted stimulation corrects the underlying chemical imbalance in the nigrostriatal pathway, supporting the modulation of motor circuits that govern the capacity for voluntary movement.

Dosage and Administration Information

Official Administration Guidelines for Levopar Plus

Levopar Plus (Co-beneldopa) is a fixed-dose combination medication for oral administration, available as standard tablets, dispersible tablets, and modified-release capsules. Its use is defined by a mandatory titration period, precise timing relative to meals, and specific handling instructions.

Administration Scope Official Instruction (Levodopa/Benserazide)
Initial Dosing Treatment starts gradually with 50 mg / 12.5 mg to 100 mg / 25 mg 3 to 4 times daily.
Dose Adjustment The daily dose is increased slowly, generally every 3 to 7 days, until an optimal dose is reached, typically between 300 mg and 800 mg Levodopa per day.
Maximum Dose It is rarely necessary to administer more than 1000 mg of Levodopa per day.
Meal Timing Standard and dispersible forms must be taken 30 minutes before or 1 hour after a meal to prevent competition with dietary proteins.
Missed Dose If a dose is missed, it should be skipped. The next dose must be taken at the scheduled time; do not take a double dose.
Form-Specific Rules Modified-release capsules must be swallowed whole; they must never be chewed or crushed. Discontinuation of therapy requires a gradual dose reduction.
Age Restriction The medicine is not to be administered to patients under the age of 25.

Connection to the Overall Use Protocol: The official use protocol is characterized by a cautious, incremental titration phase designed to establish the required long-term dose. This stable regimen is then maintained using multiple, divided doses administered daily. Adherence to the prescribed timing and form-specific handling is critical, as these conditions ensure the proper absorption and controlled delivery of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levopar Plus

Evidence for Use in Idiopathic Parkinson's Disease (General Management)

The use of Levopar Plus (Co-beneldopa) in the primary management of Idiopathic Parkinson's Disease has been the subject of numerous randomized controlled trials (RCTs) and systematic reviews. This large body of research was conducted exploring how outcomes related to motor function were measured over defined time intervals. Studies included a variety of adult and older adult populations, covering different phases of the condition. Findings reported across the studies document patterns observed in the measured severity of motor symptoms and in outcomes related to the patients' ability to perform daily activities. The challenge of the short half-life suggests the need for future research into sustaining stable symptom management.

Evidence for Managing Motor Fluctuations in Advanced Disease

Research has also explored the use of Levopar Plus in patients with advanced Parkinson's disease who experience fluctuating or unstable symptoms, such as the "wearing-off" phenomenon. These studies were typically designed as crossover trials comparing different formulations (e.g., standard versus dispersible tablets) to observe how measured outcomes differed. The main focus of these trials was to monitor the speed with which the medicine begins to be measured as having its measured response and to track the measured difference between time spent in the "OFF" state and time spent in the "ON" state. A key limitation here is that studies evaluating specific advanced formulations often involve smaller populations in short-term comparative settings, meaning the results apply only to the specific populations studied.

Research Gaps and Limitations

Research highlights several areas where data remains limited. One major limitation across the entire research base is that the sample sizes were modest and the follow-up durations were limited in the most rigorous comparative studies. Limited information for long-term outcomes means that the durability of the measured response and the evolution of symptoms over many years are not fully detailed by pivotal clinical trials. Furthermore, the influence of factors outside the central nervous system on drug absorption means findings were mixed in some studies regarding how patient-specific factors influence the measured outcomes. Research provides context; however, individual experiences may differ from group patterns.

Key Studies & References

  1. Comparison of the effects of a soluble and a standard formulation of levodopa/benserazide on motor fluctuations in Parkinson's disease

Frequently Asked Questions (FAQ)

Common questions about Levopar Plus (FAQ)


Q: What are the benefits of taking Levopar Plus for movement disorders?

A: According to official product information, Levopar Plus is used to treat the symptoms of Parkinson's disease. Its primary function is to help control the physical manifestations of the condition, such as slow movements, muscle stiffness, and tremor. It does this by helping to restore the necessary chemical balance in the brain’s motor control areas.


Q: How quickly should I expect Levopar Plus to start working?

A: Regulatory documents indicate that for the standard formulation, the onset of measurable action is often observed within 30 to 60 minutes after administration. Individual response times may vary.


Q: What is the expected time for Levopar Plus to reach its full effect?

A: Reaching the maximum or full effect of Levopar Plus is a gradual process. Treatment begins with a small initial dose that is slowly and incrementally increased, a process called titration, over several days or weeks. This allows the prescribing professional to determine the optimal dose for symptom management.


Q: What happens if I miss a dose of Levopar Plus?

A: Official administration guidelines state that if a dose is missed, it should be skipped entirely. The guidance is to take the next dose at its regularly scheduled time. Official recommendations caution against taking a double dose to compensate for a missed one.


Q: Can Levopar Plus cause difficulty sleeping?

A: Yes, regulatory safety documents list difficulty sleeping as a possible side effect of this medicine. Specifically, psychiatric disturbances such as insomnia (difficulty falling asleep) and excessive dreaming have been reported as common occurrences.


Q: Is feeling dizzy a common side effect of Levopar Plus?

A: Yes, dizziness is a commonly reported effect, particularly when moving from a sitting or lying position to a standing position (orthostatic hypotension). This is a known effect on blood pressure that is generally addressed through clinical management.


Q: Do most people experience nausea when starting Levopar Plus?

A: Nausea and vomiting are listed in regulatory documents as common side effects that often manifest during the initial phase of treatment. While common, the official product information does not provide an exact percentage of the population who may experience these effects.


Q: Are there any serious side effects I should watch out for while on Levopar Plus?

A: Yes, serious adverse effects are documented in official safety information. These include a sudden onset of sleep attacks, severe changes in heart rhythm, and a syndrome similar to Neuroleptic Malignant Syndrome if the drug is suddenly withdrawn. Allergic reactions are also possible.


Q: Does Levopar Plus make you feel drowsy or tired?

A: Official safety information reports that one component of the medicine can cause drowsiness or sleepiness (somnolence). In rare instances, this effect has been reported to lead to falling asleep suddenly while engaging in daily activities.


Q: Is it normal to see changes in my appetite after starting Levopar Plus?

A: Yes, a loss of appetite, or a decreased desire to eat, is listed in the official product information as a common side effect. It is often noted as an effect that may occur when treatment is first initiated.


Q: Can Levopar Plus be taken with antacids?

A: According to regulatory information, the concomitant use of antacid preparations should generally be avoided. Antacids can interfere with the absorption of Levopar Plus, potentially altering how much of the medicine gets into the body.


Q: Are there any known interactions between Levopar Plus and common cold medicines?

A: Interactions are known to exist with certain ingredients found in common cold remedies. Specifically, medicines containing sympathomimetics (such as decongestants) or certain antihistamines may potentiate (increase) side effects like dizziness, confusion, or changes in heart rate.


Q: Does Levopar Plus affect blood pressure?

A: Yes, official safety data indicates that Levopar Plus can affect the circulatory system. It is known to commonly cause orthostatic hypotension (low blood pressure when standing) and is also associated with reports of hypertension (high blood pressure).


Q: Can taking Levopar Plus cause involuntary movements?

A: Yes, uncontrolled, involuntary movements of the body (dyskinesia or hyperkinesia) are documented as a common side effect. Regulatory sources note that these types of movements typically become more apparent with prolonged, long-term use.


Q: Can Levopar Plus cause difficulty driving?

A: Official regulatory warnings advise caution regarding driving. Since the medicine can cause sleepiness, drowsiness, or even sudden sleep attacks, driving or operating machinery should be avoided if these effects occur.


Q: Why do some people feel anxious or agitated on Levopar Plus?

A: Anxiety and agitation are recognized side effects of Levopar Plus, which fall under the category of psychiatric disturbances. These effects are related to how the medicine acts on the central nervous system.


Q: Does Levopar Plus have any effect on mood or depression?

A: Yes, official product information reports that changes in mood are possible. Reported side effects include feeling anxious, agitated, or experiencing depression.


Q: Can Levopar Plus make me feel lightheaded when I stand up?

A: Yes, official safety observations indicate that feeling lightheaded or dizzy when standing is possible. This is a sign of orthostatic hypotension, which is a drop in blood pressure caused by the medication.


Q: How does my body process and eliminate Levopar Plus?

A: According to the drug's pharmacokinetics, the active ingredients are processed and broken down through metabolism. The main route of elimination for the medicine and its byproducts is via the kidneys and subsequently through the urine.


Q: Can Levopar Plus interact with alcohol?

A: Official interaction warnings note that alcohol consumption can potentiate (increase) nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.


Q: Is it possible for Levopar Plus to make symptoms worse initially?

A: Yes, official safety information reports that an initial worsening of some Parkinsonian symptoms, such as slowness of movement (bradykinesia), is a recognized side effect that may occur when starting treatment. This is typically managed during the dose adjustment phase.


Q: What does 'Plus' signify in the drug name Levopar Plus?

A: The term 'Plus' in Levopar Plus signifies that the medicine is a fixed-dose combination product. It contains two active ingredients—levodopa and benserazide—which are combined to enhance the effective delivery of the medication to the brain.


Q: Are there different strengths of Levopar Plus tablets?

A: Yes, official regulatory documents confirm that the medicine is available in different strengths. These strengths are identified by the combined dosage of levodopa and benserazide, such as the 100 mg/25 mg and 50 mg/12.5 mg ratios used for treatment initiation.


Q: Does the color or shape of the Levopar Plus pill matter?

A: Yes, the physical appearance of the pill is important. Different formulations, such as standard tablets versus modified-release capsules, often have distinct colors or shapes to help distinguish them. Furthermore, each form may have specific administration rules, such as some capsules needing to be swallowed whole.


Q: When is the best time of day to take Levopar Plus?

A: Regulatory guidance suggests that the medicine is usually taken multiple times throughout the day at consistent intervals. For patients who experience immobility problems during the night, clinical protocols may involve adjusting the final evening dose.


Q: Does Levopar Plus lose effectiveness over time?

A: Official medical information states that the effectiveness of the drug can change over time. Many patients may experience what is known as 'motor fluctuations' or the 'wearing-off' phenomenon, where the therapeutic effects of each individual dose become noticeably shorter.

How should Levopar Plus be stored and disposed of?

How to Store and Dispose of Levopar Plus

Official regulatory guidelines mandate specific conditions for storing and disposing of levodopa-carbidopa medicines, such as Levopar Plus, to maintain stability and safety.


Storage Requirements

  • Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Protect the medicine from excess heat and freezing.
  • Protection: Keep the medication in its original, tightly closed container to protect it from moisture and light.
  • Stability: If the container is a bottle, the contents may need to be discarded within three months of opening, even if the general expiration date is later. Follow the specific instructions on the packaging.
  • Child Safety: Medication must be stored out of the sight and reach of children.

Disposal Instructions

  • Waste Management: Do not dispose of unused or expired Levopar Plus by flushing it down a toilet or throwing it into household trash.
  • Collection: Unwanted medicine should be disposed of through a designated drug take-back program or pharmacy collection point to comply with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levopar Plus found in:

A-Z Index: